Department of Genetic Engineering, CINVESTAV, Irapuato, Guanajuato, Mexico. pilarica03@gmail.com.
Department of Medical Sciences, Division of Health Sciences, León Campus, University of Guanajuato, 20 de Enero no. 929, 37320, León, Guanajuato, Mexico. szaina@ugto.mx.
Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Av. Gran Vía s/n km. 2.7, 08907 L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain. szaina@ugto.mx.
Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Av. Gran Vía s/n km. 2.7, 08907 L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain. hheyn@idibell.cat.
Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Av. Gran Vía s/n km. 2.7, 08907 L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain. fjcarmona@idibell.cat.
Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Av. Gran Vía s/n km. 2.7, 08907 L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain. varolnur@gmail.com.
Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Av. Gran Vía s/n km. 2.7, 08907 L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain. s.sayolspuig@imb-mainz.de.
Department of Pathology, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain. ecm@bellvitgehospital.cat.
Department of Pathology and Experimental Therapeutics, University of Barcelona, Barcelona, Catalonia, Spain. ecm@bellvitgehospital.cat.
Department of Anatomic Pathology, Hospital Clinic, University of Barcelona, Barcelona, Catalonia, Spain. jramirez@clinic.ub.es.
Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Av. Gran Vía s/n km. 2.7, 08907 L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain. agomezm@idibell.cat.
Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Av. Gran Vía s/n km. 2.7, 08907 L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain. smoran@idibell.cat.
Department of Genetic Engineering, CINVESTAV, Irapuato, Guanajuato, Mexico. glund@ira.cinvestav.mx.
Department of Genetic Engineering, CINVESTAV, Irapuato, Guanajuato, Mexico. drodrigu@ira.cinvestav.mx.
Bachelor's Degree in Nutrition Programme, Division of Health Sciences, León Campus, University of Guanajuato, León, Guanajuato, Mexico. glg_2025@hotmail.com.
Bachelor's Degree in Nutrition Programme, Division of Health Sciences, León Campus, University of Guanajuato, León, Guanajuato, Mexico. magda.mrna@gmail.com.
Department of Genetic Engineering, CINVESTAV, Irapuato, Guanajuato, Mexico. crocha@ira.cinvestav.mx.
University DNA Massive Sequencing Unit, Institute of Biotechnology, UNAM, Cuernavaca, Morelos, Mexico. alexsf@ibt.unam.mx.
Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Av. Gran Vía s/n km. 2.7, 08907 L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain. mesteller@idibell.cat.
Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Catalonia, Spain. mesteller@idibell.cat.
Institució Catalana de Recerca i Estudis Avançats (ICREA), 08010, Barcelona, Catalonia, Spain. mesteller@idibell.cat.
background: Atherosclerosis severity-independent alterations in DNA methylation, a reversible and highly regulated DNA modification, have been detected in aortic atheromas, thus supporting the hypothesis that epigenetic mechanisms participate in the pathogenesis of atherosclerosis. One yet unaddressed issue is whether the progression of atherosclerosis is associated with an increase in DNA methylation drift in the vascular tissue. The purpose of the study was to identify CpG methylation profiles that vary with the progression of atherosclerosis in the human aorta.
methods: We interrogated a set of donor-matched atherosclerotic and normal aortic samples ranging from histological grade III to VII, with a high-density (>450,000 CpG sites) DNA methylation microarray.
results: We detected a correlation between histological grade and intra-pair differential methylation for 1,985 autosomal CpGs, the vast majority of which drifted towards hypermethylation with lesion progression. The identified CpG loci map to genes that are regulated by known critical transcription factors involved in atherosclerosis and participate in inflammatory and immune responses. Functional relevance was corroborated by crossing the DNA methylation profiles with expression data obtained in the same human aorta sample set, by a transcriptome-wide analysis of murine atherosclerotic aortas and from available public databases.
conclusions: Our work identifies for the first time atherosclerosis progression-specific DNA methylation profiles in the vascular tissue. These findings provide potential novel markers of lesion severity and targets to counteract the progression of the atheroma.